|
BP13049
|
USP7-IN-8
|
|
|
|
|
Benzamide, 4-[6-amino-4-ethyl-5-(4-hydroxyphenyl)-3-pyridinyl]-N-methyl- is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM. USP7-IN-8 has anticancer effects.
|
|
BP13050
|
Benzamidine hydrochloride
|
|
|
|
|
Benzamidine HCl is a reversible inhibitor of serine proteases, including trypsin, plasmin, and thrombin (Ki of 35, 350, and 220 μM, respectively).
|
|
BP13051
|
Benzo[b]thiophene-2-sulfonamide, N-[3-(aminomethyl)phenyl]-5-chloro-3-methyl-
|
|
|
|
|
Benzo[b]thiophene-2-sulfonamide, N-[3-(aminomethyl)phenyl]-5-chloro-3-methyl- directly inhibits InhA and does not require activation by the catalase peroxidase KatG.
|
|
BP13052
|
β-Boswellic acid
|
|
|
|
|
Beta-boswellic acid and its derivatives (the major constituents of Boswellin) have anti-carcinogenic, anti-tumor, and anti-hyperlipidemic activities.
|
|
BP13053
|
BI-1347
|
|
|
|
|
BI-1347 is a potent, selective inhibitor of CDK8/cyclinC (IC50: 1 nM). It shows tumor growth inhibition in an in vivo xenograft model.
|
|
BP13054
|
BI-847325
|
|
|
|
|
BI-847325 is a selective dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively.
|
|
BP13055
|
BioE-1115
|
|
|
|
|
BioE-1115 is a selective and potent inhibitor of serine-threonine protein kinase (PASK, IC50 = 4 nM). BioE-1115 is a potent inhibitor of CK2α (IC50 = 10 μM).
|
|
BP13056
|
bio-THZ1
|
|
|
|
|
bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM).
|
|
BP13057
|
Bisindolylmaleimide X hydrochloride
|
|
|
|
|
Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).
|
|
BP13058
|
Bleomycin Sulfate
|
|
|
|
|
Bleomycin Sulfate, a glycopeptide antibiotic, is an anticancer agent for squamous cell carcinomas (SCC). In UT-SCC-19A cells, the IC50 of Bleomycin Sulfate is 4 nM.
|
|
BP13059
|
BML-259
|
|
|
|
|
BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenerative diseases.
|
|
BP13060
|
BMS-265246
|
|
|
|
|
BMS-265246 is a potent and selective CDK1/2 inhibitor.
|
|
BP13061
|
BMS-3
|
|
|
|
|
BMS-3 is a potent LIMK inhibitor with IC50s of 5 nM and 6 nM for LIMK1 and LIMK2, respectively.
|
|
BP13062
|
BMS-5
|
|
|
|
|
BMS-5 is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.
|
|
BP13063
|
BMS-8
|
|
|
|
|
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.
|
|
BP13064
|
Bohemine
|
|
|
|
|
Bohemine is a cyclin-dependent kinase inhibitor.
|
|
BP13065
|
Bractoppin
|
|
|
|
|
Bractoppin is a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem (t)BRCT domain (IC50 = 0.074 μM), which selectively inhibits substrate binding with nanomolar potency in vitro. Structure-activity exploration suggests that Bractoppin engages BRCA1 tBRCT residues recognizing pSer in the consensus motif, pSer-Pro-Thr-Phe, plus an abutting hydrophobic pocket that is distinct in structurally related BRCT domains, conferring selectivity.
|
|
BP13066
|
BRD32048
|
|
|
|
|
BRD32048 is a top candidate ETV1 perturbagen. BRD32048 inhibits p300-dependent acetylation of ETV1, thereby promoting its degradation.
|
|
BP13067
|
BRD6989
|
|
|
|
|
BRD6989 is an analog of the natural product cortistatin A (dCA). Which inhibits CDK8 and upregulates IL-10. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes. BRD6989 selectively binds a complex of CDK8 with an IC50 of ~200 nM.
|
|
BP13068
|
Brequinar
|
|
|
|
|
Brequinar is a potent inhibitor of dihydroorotate dehydrogenase, with potent activities against a broad spectrum of viruses.
|
phenyl]-5-chloro-3-methyl-.gif)
